Contents
1. The overview of “AbbVie Inc.”
2. The detailed data of “AbbVie Inc.”
3. The map of “AbbVie Inc.”
4. The stock weekly chart of “AbbVie Inc.”
5. The stock weekly trading radar of “AbbVie Inc.”
6. The annual filings of “AbbVie Inc.”
7. The stock price of “AbbVie Inc.”
* Last update: February 10, 2022
The overview of “AbbVie Inc.”
“AbbVie Inc.” is a Biopharmaceutical company established in April 2012 in Delaware, in the U.S.. “Abbott Laboratories“, a pharmaceutical company, spun off the research-based pharmaceutical business to “AbbVie Inc.” on January 1, 2013, so the businesses regarding the two kinds of anti-HIV drug, Adalimumab and Lopinavir/Ritonavir were inherited to them. After that, the company was listed on the New York Stock Exchange (NYSE) on January 2, 2013. Currently, the company is headquartered in North Chicago, Illinois in the U.S. and mainly manage the development and marketing businesses for new drugs. Also, the drugs have been using in more than 170 countries in the world. (As of December 2015)
On May 26, 2015, “AbbVie Inc.” acquired “Pharmacyclics LLC”, Biopharmaceutical company, for approximately 21 billion USD. Also, on April 28, 2016, the company acquired cancer drug startup “Stemcentrx, Inc.” for approximately 9.8 billion USD, in addition to this, on June 25, 2019, the company acquired “Allergan plc”, the Irish healthcare company that researches, develops, and sells pharmaceuticals and medical devices related to aesthetic medicine, breast surgery, and ophthalmology for approximately 63 billion USD.
Whereas, in July 2020, the company announced it would acquire “Mavupharma Inc.” that is a company for cancer drug, further more “Allergan Aesthetics” announced it would acquire “Soliton”.
The detailed data of “AbbVie Inc.”
●Established date： April 10, 2012
●Location： 1400 Sheridan Rd, North Chicago, IL 60064
●Stock Exchange： NYSE（ABBV）
●Listing date： January 2, 2013
●Business details： Development and marketing of drugs including new pharmaceuticals（Biotechnlogy）
●Official website： https://www.abbvie.com/
The map of “AbbVie Inc.”
The stock weekly chart of “AbbVie Inc.”
The stock weekly trading radar of “AbbVie Inc.”
The annual filings of “AbbVie Inc.”
* Date: Feb 21, 2020
* in millions USD
| Cutoff date | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|
| Operating income | 11,363 | 12,983 | 6,383 |
| Net income attributable | 4,616 | 7,882 | 5,687 |
| Total current assets | 24,173 | 49,519 | 16,945 |
| Total current liabilities | 28,661 | 15,585 | 17,239 |
| Current ratio (1.2 or more is the best) | 0.84 | 3.18 | 0.98 |
| Common stock and additional paid-in capital | 15,138 | (9,293) | (9,334) |
| Treasury stock | N/A | N/A | N/A |
| Retained earning, Accumulated deficit | 1,055 | 4,717 | 3,368 |
| Total stockholders' equity | 13,076 | (8,172) | (8,446) |
| Total equity and liabilities | 150,565 | 89,115 | 59,352 |
| Equity ratio (20% or more is better) (50% or more is the best) | 8.68% | 0.00% | 0.00% |
| Cash flows from operating activities | 17,588 | 13,324 | 13,427 |
| Cash flows from investing activities | (37,557) | 596 | (1,006) |
| Cash flows from financing activities | (11,501) | 18,708 | (14,396) |
| Free cash flow | (19,969) | 13,920 | 12,421 |
The stock price of “AbbVie Inc.”
Net income, Current ratio, and Retained earning descended.
However, Total stockholders' equity has turned positive.
That's why, the company got 8.68% Equity.
Also, Free cash flow turned to a major negative from positive situation.
That's why, it's difficult to forecast stock-price trend in 2021.
* Comment
Net income, Current ratio, and Retained earning ascended.
Total stockholders' equity and Total equity and liabilities also ascended.
However, Total stockholders' equity is negative even now.
Also, Free cash flow ascended a little.
That's why, it's difficult to forecast stock-price trend in 2020.
| Term year | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Entity min stock price in monthly chart | N/A | approx 102.40 (Jan) | approx 72.00 (Apr) | approx 65.73 (Aug) |
| Entity max stock price in monthly chart | N/A | approx 135.40 (Dec) | approx 107.00 (Dec) | approx 91.75 (Jan) |
| Stock price increase ratio (50% or more is the best) | N/A | 32.23% | 48.61% | 39.59% |
